

Dynamics of the Delta and Omicron variants of SARS-CoV-2 in the United States: the battle of supremacy in the presence of vaccination, mask usage and antiviral treatment

Calistus N. Ngonghala^{1, 2, *}, Hemaho B. Taboe³, and Abba B. Gumel^{4, 5}

¹ *Department of Mathematics, University of Florida, Gainesville, FL 32611, USA.*

² *Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610, USA.*

³ *Laboratoire de Biomathématiques et d'Estimations Forestières, University of Abomey-Calavi, Cotonou, Bénin.*

⁴ *School of Mathematical and Statistical Sciences, Arizona State University, Tempe, Arizona, 85287, USA.*

⁵ *Department of Mathematics and Applied Mathematics, University of Pretoria, Pretoria 0002, South Africa.*

Online supplementary material

1 Brief description of model variables and parameters

Table S1: Description of the state variables of the model (2.7). The subscript $j = d$ denotes the Delta variant and $j = o$ denotes the Omicron variant.

State variables	Description
S	Population of unvaccinated susceptible individuals (and individuals who lost their immunity over time)
V_f	Population of fully-vaccinated but not boosted individuals
V_b	Population of fully-vaccinated individuals who received the booster dose
E_j	Population of exposed (i.e., newly-infected or latent) individuals
P_j	Population of pre-symptomatically infectious individuals
A_j	Population of asymptotically-infectious individuals
Q_j	Population of detected (positive) exposed, presymptomatic and asymptomatic individuals
I_{j1}	Population of symptomatically-infectious individuals within the first five days of the onset of SARS-CoV-2 symptoms
I_{j2}	Population of symptomatically-infectious individuals that survived the first five days of the onset of SARS-CoV-2 symptoms
H_j	Population of hospitalized individuals
R_j	Population of recovered and successfully treated individuals
N	Total population ($N = S + V_f + V_b + E_d + P_d + A_d + Q_d + I_{d1} + I_{d2} + H_d + R_d + E_o + P_o + A_o + Q_o + I_{o1} + I_{o2} + H_o + R_o$)

*Corresponding author: Calistus N. Ngonghala, email: calistusnn@ufl.edu

Table S2: Description of the parameters of the model (2.7). Notation: $j \in \{d, o\}$, where the subscript d denotes the Delta variant and the subscript o denotes the Omicron variant.

Parameter	Description
Λ	Recruitment rate (by birth or immigration) into the population
μ	Natural death rate
β_{jk}	Effective contact rate for infectious individuals in P_j class ($k = p$), A_j class ($k = a$), I_{jk} class ($k = 1, 2$), and the H_j class ($k = h$)
ξ_{vf}	Rate at which susceptible individuals are fully-vaccinated
ξ_{vb}	Rate at which fully -Vaccinated individuals receive the booster dose
ε_{jf}	Cross-protective efficacy of the vaccine against acquisition of the Delta ($j = d$) or Omicron ($j = o$) variant for fully-vaccinated but not boosted individuals
ε_{jb}	Cross-protective efficacy of the vaccine against acquisition of the Delta ($j = d$) or Omicron ($j = o$) variant for boosted individuals
ω_{jf}	Rate of waning of vaccine-derived immunity for fully- vaccinated but not boosted individuals
ω_{jb}	Vaccine waning rate for fully-vaccinated and boosted individuals
ω_{jr}	Rate of loss of infection-acquired (natural) immunity
σ_{je}	Progression rate of exposed humans to the presymptomatically-infectious stage
σ_{jp}	Progression rate of presymptomatically-infectious individuals at the end of the incubation period to the asymptotically-infectious (A_j) or the first symptomatically-infectious (I_{d1}) class
α_{j1}	Transition rate of individuals from the I_{j1} to the I_{j2} class (i.e., $1/\alpha_{j1} = 5$ days)
ρ_j	Detection or positivity rate of exposed, presymptomatic and asymptomatic individuals
ψ_j	Rate at which detected individuals develop symptoms
$r_j(1 - r_j)$	Proportion of presymptomatically-infectious individuals who exhibit (do not exhibit) clinical symptoms of SARS-CoV-2 at the end of the incubation period
ϕ_{j1} (ϕ_{j2})	Hospitalization rate of individuals in the I_{j1} (I_{j2}) class
γ_{ja} (γ_{jq})	Natural recovery rate for individuals in the A_j (Q_j) (I_{j2}) (H_j) class
(γ_{j2}) (γ_{jh})	
τ_{j1} (τ_{j2})	Treatment rate of individuals in the I_{j1} (I_{j2}) (H_j) class
(τ_{jh})	
δ_{j1} (δ_{j2}) (δ_{jh})	Disease-induced death rate of symptomatically-infectious humans in the I_{j1} (I_{j2}) (H_j) class

2 Fixed and estimated baseline parameter values

Table S3: Fixed baseline parameter values of the model (2.7). Apart from the vaccine efficacies ($\varepsilon_j, \varepsilon_{jk}, j \in \{d, o\}, k \in \{b, f\}$), and the proportions r_j , which are dimensionless, all the other parameters have units of *per day*. Notation: * represents “adapted from” the cited reference.

Parameter	Value	Source	Parameter	Value	Source	Parameter	Value	Source
Λ	11400	[1]	α_{d1}, α_{o1}	1/5	[4]	σ_{dp}, σ_{op}	1/2	[11]
μ	3.4×10^{-5}	[1]	ω_{vf}	1/274	[5]*	ϕ_{d1}, ϕ_{o1}	1/5	[11]*
ξ_{vf}	1.9×10^{-5}	[2]	ω_{vb}	1/365	[5]*	ϕ_{d2}, ϕ_{o2}	1/3	[11]*
ξ_{vb}	2.6×10^{-5}	[2]	ω_{dr}, ω_{or}	1/274	[5]	γ_{da}	1/5	[13]
δ_{dh}	1.0×10^{-4}	[1]*	r_d, r_o	0.200	[6, 7]	γ_{oa}	2/5	[13]*
δ_{oh}	5.0×10^{-5}	[1]*	ε_{df}	0.950	[8]	γ_{dh}, γ_{dq}	1/5	[13]*
δ_{d1}	2.5×10^{-5}	[1]*	ε_{of}	0.880	[9]	γ_{oh}, γ_{oq}	2/5	[13]*
δ_{o1}	1.3×10^{-5}	[1]*	ε_{db}	0.950	[10]	γ_{d2}	1/4	[13]*
δ_{d2}	5.0×10^{-5}	[1]*	ε_{ob}	0.755	[9]	γ_{o2}	2/4	[13]*
δ_{o2}	2.5×10^{-5}	[1]*	σ_{de}	1/5	[11]	ψ_d	1/3	[11]*
ρ_d, ρ_o	1.2×10^{-4}	[3]	σ_{oe}	1/3	[12]	ψ_o	1/3	[11, 12]*

Table S4: Estimated (fitted) baseline parameter values and confidence intervals (CIs) for the basic model (2.7) using COVID-19 confirmed case data for the US for the period from November 28, 2021 to February 2, 2022. The unit of each of the estimated community transmission rate is *per day*.

(a) Delta variant related parameters. For this baseline set of parameter values, $\mathbb{R}_{dv} = 0.2782$, with 95% CI [0.1991, 0.5197]. The basic reproduction number is $\mathbb{R}_{0d} = 0.6929$, with 95% CI [0.2914, 1.3668].

(b) Omicron variant related parameters. For this set of parameter values, $\mathbb{R}_{ov} = 0.9602$ with 95% CI [0.6206, 1.7509]. The basic reproduction number is $\mathbb{R}_{0o} = 2.0587$ with 95% CI [0.8732, 3.9008].

Parameter	value	95% CI	Parameter	value	95% CI
β_{dp}	0.331690	[0.14489240, 0.44988790]	β_{op}	0.995070	[0.43467720, 1.34966370]
β_{da}	0.003185	[0.00024100, 0.13617420]	β_{oa}	0.009555	[0.00072300, 0.40852260]
β_{d1}	0.024774	[0.00151000, 0.18891280]	β_{o1}	0.074322	[0.00453000, 0.56673840]
β_{d2}	0.000579	[0.00000010, 0.00097120]	β_{o2}	0.001737	[0.00000030, 0.00291360]
β_{dq}	0.000008	[0.00000001, 0.00018700]	β_{oq}	0.000024	[0.00000003, 0.00056100]
β_{dh}	0.000004	[0.00000001, 0.00008820]	β_{oh}	0.000012	[0.00000003, 0.00026460]
ξ_{vf}	0.005863	[0.00179810, 0.00643250]	ξ_{vf}	0.005863	[0.00179810, 0.00643250]
ξ_{vb}	0.000992	[0.00030424, 0.00108838]	ξ_{vb}	0.000992	[0.00030424, 0.00108838]

3 Assessing the combined impact of masking up and vaccination




Figure S1: Contour plot of the control reproduction number of the model (2.7) as a function of the vaccine rate coverage (ξ_{vf}) and additional mask coverage (c_m) for additional (a) cloth mask coverage (i.e., $\varepsilon_m = 0.30$), (b) surgical mask coverage (i.e., $\varepsilon_m = 0.70$), and (c) N95 mask coverage (i.e., $\varepsilon_m = 0.95$). The other parameters used are given in Tables S3 and Table S4.

4 Assessing the impact of vaccination and waning vaccine-derived immunity




Figure S2: Contour plot of the control reproduction number of the model (2.7) as a function vaccine-derived immunity waning rate for fully vaccinated individuals (ω_{vf} per day) and the vaccination rate (ξ_{vf} per day) when there is (a) no additional mask coverage beyond the baseline coverage, (b) a 10% increase in surgical mask compliance, (c) a 10% increase in N95 mask compliance. The other parameters used are given in Tables S3 and Table S4.

4.1 Assessing the impact of detecting exposed, presymptomatic, and asymptomatic cases

The model (2.7) is further simulated to assess the impact of detection of exposed, presymptomatic and asymptomatic infectious humans (through testing) and the impact of the length of time it takes for vaccine-derived immunity to wane completely. For the first set of simulations, the detection rate of exposed, presymptomatic and asymptomatic infectious individuals with the Delta or the omicron variant, which are assumed to be the same in this study (i.e., $\rho_d = \rho_o$) is scaled by 25, 50, and 75. The simulation results obtained, depicted in Figure S3 (a) and (c), show an increase in the confirmed daily (Figure S3 (a)) and cumulative (Figure S3 (c)) cases of COVID-19 in the U.S. with increasing detection of exposed, presymptomatic and asymptomatic infectious individuals. For example, if the detection rate is 25 times the baseline value, there is a 4% increase in the peak number of confirmed cases (magenta curve in Figure S3(a)). However, if the detection rate increases to 75 times the baseline value, then there is a 9% increase in the peak number of confirmed cases (green curve in Figure S3(a)). Similar increases in cumulative cases are recorded as the detection rate of exposed, presymptomatic and asymptomatic infectious individuals increases (Figure S3 (c)).




Figure S3: Simulations of the model (2.7) depicting the impact of detecting exposed, presymptomatic, and asymptomatic infectious individuals on the (a) the new daily and (b) cumulative COVID-19 cases in the US. The other parameter values used for the simulations are presented in Tables S3 and S4.

References

- [1] C. N. Ngonghala, J. R. Knitter, L. Marinacci, M. H. Bonds, and A. B. Gumel, “Assessing the impact of widespread respirator use in curtailing covid-19 transmission in the usa,” *Royal Society open science* **8**, 210699 (2021).
- [2] Centers for Disease Control and Prevention, “Different COVID-19 vaccines,” CDC information (Accessed on January 25, 2021).
[Online Version](#)
- [3] H. Ritchie, E. Ortiz-Ospina, D. Beltekian, E. Mathieu, J. Hasell, B. Macdonald, C. Giattino, and M. Roser, “Coronavirus (COVID-19) vaccinations,” *Statistics and Research, Our World in Data* (Accessed on January 24, 2021).
- [4] Centers for Disease Control and Prevention, “Coronavirus disease 2019 (COVID-19),” National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases (Accessed on March 4, 2020).
[Online Version](#)
- [5] B. Curley, “How long does immunity from COVID-19 vaccination last?” *Healthline* (Accessed on June 11, 2021).
[Online Version](#)
- [6] World Health Organization, “Coronavirus disease 2019 (COVID-19): situation report, 46,” WHO (2020).
- [7] Z. Wu and J. M. McGoogan, “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention,” *JAMA* (2020).
- [8] F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. P. Marc, E. D. Moreira, C. Zerbini, et al., “Safety and efficacy of the bnt162b2 mrna covid-19 vaccine,” *New England Journal of Medicine* (2020).
- [9] N. Andrews, J. Stowe, F. Kirsebom, S. Toffa, T. Rickeard, E. Gallagher, C. Gower, M. Kall, N. Groves, A.-M. O’Connell, et al., “Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern,” *MedRxiv* (2021).
- [10] Y. M. Bar-On, Y. Goldberg, M. Mandel, O. Bodenheimer, L. Freedman, N. Kalkstein, B. Mizrahi, S. Alroy-Preis, N. Ash, R. Milo, et al., “Protection of bnt162b2 vaccine booster against covid-19 in israel,” *New england journal of medicine* **385**, 1393–1400 (2021).

- [11] N. M. Linton, T. Kobayashi, Y. Yang, K. Hayashi, A. R. Akhmetzhanov, S.-m. Jung, B. Yuan, R. Kinoshita, and H. Nishiura, “Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data,” *Journal of Clinical Medicine* **9**, 538 (2020).
- [12] L. Jansen, B. Tegomoh, K. Lange, K. Showalter, J. Figliomeni, B. Abdalhamid, P. C. Iwen, J. Fauver, B. Buss, and M. Donahue, “Investigation of a sars-cov-2 b. 1.1. 529 (omicron) variant cluster—nebraska, november–december 2021,” *Morbidity and Mortality Weekly Report* **70**, 1782 (2021).
- [13] S. Kissler, C. Tedijanto, E. Goldstein, Y. Grad, and M. Lipsitch, “Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period,” *Science* (2020).
[Online Version](#)